Search

Now showing items 1-10 of 13

Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.

Dubuisson, N; Bauer, A; Buckley, M; Gilbert, R; Paterson, A; Marta, M; Gnanapavan, S; Turner, B; Baker, D; Giovannoni, G;... (2017-10)

BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...

CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE

Pakpoor, J; Disanto, G; Altmann, DR; Pavitt, S; Turner, B; Calado-Marta, M; Juliusson, G; Baker, D; Chataway, J; Schmierer, K (2014-10)

Disease modification in advanced MS: Focus on upper limb function.

Dubuisson, N; Baker, D; Thomson, A; Marta, M; Gnanapavan, S; Turner, B; Giovannoni, G; Schmierer, K (2017-12)

Inclusion criteria used in trials of people with progressive multiple sclerosis.

Dubuisson, N; Marta, M; Gnanapavan, S; Turner, B; Baker, D; Thomson, A; Schmierer, K; Giovannoni, G (2020-03)

Importance of upper limb function in advanced multiple sclerosis

Thomson, A; Giovannoni, G; Marta, M; Gnanpavan, S; Turner, B; Baker, D; Schmierer, K (2016-09)

Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients

Allen-Philbey, K; De Trane, S; Stennett, A; Yildiz, O; Adams, A; Turner, B; Marta, M; Gnanapavan, S; Bianchi, L; Mathews, J;... (2021-06)

This is the accepted manuscript of an article published online: 1. ACTRIMS Forum 2021 – Poster Presentations. Multiple Sclerosis Journal. 2021;27(1_suppl):15-122. doi:10.1177/13524585211015908

Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study

Smets, I; Holden, D; Bianchi, L; Ammoscato, F; Allen-Philbey, K; Baker, D; Turner, B; Marta, M; Giovannoni, G; MacDougall, A;... (2021)

CLADRIPLAS: Does cladribine Target CNS plasma cells and reduce neuro-axonal damage in people with MS?

Allen-Philbey, K; Andrews, M; Redha, I; Papachatzaki, M; Marta, M; Gnanapavan, S; Mathews, J; Turner, B; Giovannoni, G; Baker, D;... (2022)

Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study

Smets, I; Holden, D; Bianchi, L; Ammoscato, F; Allen-Philbey, K; Baker, D; Turner, B; Marta, M; Giovannoni, G; Macdougall, A;... (2022)

Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients

Allen-Philbey, K; De Trane, S; Stennett, A; Yildiz, O; Adams, A; Turner, B; Marta, M; Gnanapavan, S; Bianchi, L; Mathews, J;... (2020)